Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients

被引:64
作者
Beenakker, EAC [1 ]
Maurits, NM [1 ]
Fock, JM [1 ]
Brouwer, OF [1 ]
van der Hoeven, JH [1 ]
机构
[1] Univ Groningen Hosp, Dept Neurol, NL-9700 RB Groningen, Netherlands
关键词
muscle force; timed tests; children; Duchenne muscular dystrophy;
D O I
10.1016/j.ejpn.2005.06.004
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Neuromuscular disorders are characterised by progressive muscle weakness, which in time causes functional impairment. To quantify the extent of disease progression, muscle force and functional ability can be measured. Which of these parameters changes most depends on the disease stage. In a previous study, we reported normal values for muscle force obtained by handheld dynamometry in healthy children aged 4-16 years. In the present study, we report normal values for timed functional tests in healthy children aged 4-11 years. These normal values were compared with values obtained in 16 ambulant patients with Duchenne muscular dystrophy (DMD) aged 5-8 years to study the extent of functional impairment. In ambulant patients with DMD, we found that muscle function assessed by timed functional tests (running 9 m and rising up from the floor) and muscle force assessed by hand-held dynamometry were severely impaired. However, a small reduction of muscle force was accompanied by a large reduction in functional ability. Therefore, in our group of ambulant patients with DMD, timed functional testing was the most sensitive parameter to determine the extent of disease progression. Timed functional testing may therefore be considered as an additional outcome measure in drug trials to evaluate the effects of therapy in ambulant patients with DMD and possibly in other neuromuscular disorders. (c) 2005 Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.
引用
收藏
页码:387 / 393
页数:7
相关论文
共 8 条
[1]
DEFLAZACORT IN DUCHENNE DYSTROPHY - STUDY OF LONG-TERM EFFECT [J].
ANGELINI, C ;
PEGORARO, E ;
TURELLA, E ;
INTINO, MT ;
PINI, A ;
COSTA, C .
MUSCLE & NERVE, 1994, 17 (04) :386-391
[2]
Intermittent prednisone therapy in Duchenne muscular dystrophy - A randomized controlled trial [J].
Beenakker, EAC ;
Fock, JM ;
Van Tol, MJ ;
Maurits, NM ;
Koopman, HM ;
Brouwer, OF ;
Van der Hoeven, JH .
ARCHIVES OF NEUROLOGY, 2005, 62 (01) :128-132
[3]
Reference values of maximum isometric muscle force obtained in 270 children aged 4-16 years by hand-held dynamometry [J].
Beenakker, EAC ;
van der Hoeven, JH ;
Fock, JM ;
Maurits, NM .
NEUROMUSCULAR DISORDERS, 2001, 11 (05) :441-446
[4]
High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy [J].
Connolly, AM ;
Schierbecker, J ;
Renna, R ;
Florence, J .
NEUROMUSCULAR DISORDERS, 2002, 12 (10) :917-925
[5]
COTT OM, 1982, MUSCLE NERVE, V5, P291
[6]
Longitudinal data analysis: an application to construction of a natural history profile of Duchenne muscular dystrophy [J].
Hyde, SA ;
Steffensen, BF ;
Floytrup, I ;
Glent, S ;
Kroksmark, AK ;
Salling, B ;
Werlauff, U ;
Erlandsen, M .
NEUROMUSCULAR DISORDERS, 2001, 11 (02) :165-170
[7]
Kroksmark A K, 2001, Eur J Paediatr Neurol, V5, P191, DOI 10.1053/ejpn.2001.0510
[8]
Early prednisone treatment in Duchenne muscular dystrophy [J].
Merlini, L ;
Cicognani, A ;
Malaspina, E ;
Gennari, M ;
Gnudi, S ;
Talim, B ;
Franzoni, E .
MUSCLE & NERVE, 2003, 27 (02) :222-227